 IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system CNS in older and elderly healthy volunteers and Parkinsons patients No clinically significant adverse events observed Actively enrolling Phase 2a 201 clinical trial of IkT-148009 in patients with untreated Parkinsons disease BOSTON and ATLANTA , Sept. 15, 2022 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase, a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinsons disease, Parkinsons-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will present safety, tolerability, pharmacokinetics and exploratory Parkinsons assessment data from the Companys Phase 11b 101 study of IkT-148009 in Parkinsons disease at the International Congress of Parkinsons Disease and Movement Disorders tomorrow, September 16 th, 2022. 